Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma [0.03%]
系统性瘤内注射溶瘤性 Vesicular 栓塞病毒联合新辅助化疗治疗自然发生的骨肉瘤是安全的，且可增强长期生存率
Kelly M Makielski,Aaron L Sarver,Michael S Henson et al.
Kelly M Makielski et al.
Osteosarcoma is a devastating bone cancer that disproportionally afflicts children, adolescents, and young adults. Standard therapy includes surgical tumor resection combined with multiagent chemotherapy, but many patients still suffer from...
Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapy [0.03%]
癌睾丸特异性T细胞受体库的建立及其在T细胞受体基因治疗中的应用订正原文发表信息
Marije A J de Rooij,Dennis F G Remst,Dirk M van der Steen et al.
Marije A J de Rooij et al.
[This corrects the article DOI: 10.1016/j.omto.2022.11.007.]. © 2023 The Author(s).
Published Erratum
Molecular therapy oncolytics. 2023 Oct 23:31:100738. DOI:10.1016/j.omto.2023.100738 2023
Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases [0.03%]
针对腹膜的嵌合肿瘤溶瘤病毒CF17可预防胃癌腹膜转移患者的恶性腹水并改善预后
Annie Yang,Zhifang Zhang,Shyambabu Chaurasiya et al.
Annie Yang et al.
Gastric cancer (GC) peritoneal metastasis (PM) is fatal without effective therapy. We investigated CF17, a new replication-competent chimeric poxvirus, against GC cell lines in vitro and PM in an aggressive GCPM mouse model. We performed vi...
Advancements in CRISPR screens for the development of cancer immunotherapy strategies [0.03%]
CRISPR筛选在癌症免疫治疗策略开发中的进展
Yan-Ruide Li,Zibai Lyu,Yanxin Tian et al.
Yan-Ruide Li et al.
CRISPR screen technology enables systematic and scalable interrogation of gene function by using the CRISPR-Cas9 system to perturb gene expression. In the field of cancer immunotherapy, this technology has empowered the discovery of genes, ...
So Young Yoo,Jeong Heo
So Young Yoo
Erratum: Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers [0.03%]
基于配体的piggyBac工程化抗EGFR CART细胞对非小细胞肺癌安全有效（勘误）
Thanyavi Chinsuwan,Koichi Hirabayashi,Shuji Mishima et al.
Thanyavi Chinsuwan et al.
[This corrects the article DOI: 10.1016/j.omto.2023.100728.]. © 2023 The Author(s).
Published Erratum
Molecular therapy oncolytics. 2023 Oct 11:31:100735. DOI:10.1016/j.omto.2023.100735 2023
Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment [0.03%]
突破癌症治疗障碍：下一代单纯疱疹病毒基肿瘤溶瘤免疫疗法
Nikhil I Khushalani,Kevin J Harrington,Alan Melcher et al.
Nikhil I Khushalani et al.
Since the US Food and Drug Administration first approved talimogene laherparepvec for the treatment of melanoma in 2015, the field of oncolytic immunotherapy (OI) has rapidly evolved. There are numerous ongoing clinical studies assessing th...
A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling [0.03%]
一种新型 GPI锚定的转化生长因子-β受体II功能负调控型突变体使T细胞对转化生长因子-β失活
Sven H Petersen,Kays Al Badawy,Richard Hopkins et al.
Sven H Petersen et al.
Transforming growth factor β (TGF-β) is a pleiotropic cytokine expressed by a wide range of cell types and is known for hampering the effectiveness of cancer immune cell therapeutic approaches. We have designed a novel construct containin...
Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers [0.03%]
基于配体的piggyBac工程化抗EGFR嵌合抗原受体T细胞对非小细胞肺癌的安全性和有效性研究
Thanyavi Chinsuwan,Koichi Hirabayashi,Shuji Mishima et al.
Thanyavi Chinsuwan et al.
Epidermal growth factor receptor (EGFR) is overexpressed in various cancers, including non-small cell lung cancer (NSCLC), and in some somatic cells at a limited level, rendering it an attractive antitumor target. In this study, we engineer...
Allogeneic tumor cell-derived extracellular vesicles stimulate CD8 T cell response in colorectal cancer [0.03%]
同种异体肿瘤细胞来源的外泌体可刺激结直肠癌小鼠模型中CD8 T细胞的应答
Travis J Gates,Dechen Wangmo,Xianda Zhao et al.
Travis J Gates et al.
Most colorectal cancer (CRC) patients present with a microsatellite-stable phenotype, rendering them resistant to immune checkpoint inhibitors (ICIs). Among the contributors to ICI resistance, tumor-derived extracellular vesicles (TEVs) hav...